Enrique Dilone - Amicus Therapeutics Vice President - Technical Operations

FOLD Stock  USD 11.86  0.43  3.76%   

President

Dr. Enrique Dilone Ph.D. RAC. is Vice President Technical Operations of Amicus Therapeutics Inc. From August 2009 to January 2011 he served as Senior Director Quality Control and Analytical Chemistry. Prior to joining Amicus Dr. Dilon served as Executive Director of Quality and Analytics at NovaDel Pharma a specialty pharmaceutical company developing oral spray formulations from February 2007 to August 2009 since 2011.
Age 47
Tenure 13 years
Address 47 Hulfish Street, Princeton, NJ, United States, 08542
Phone609 662 2000
Webhttps://amicusrx.com
Diloné served as Senior Director/Director of Analytical Operations at OSI/Eyetech Pharmaceuticals from February 2002 to December 2006. He received a Ph.D. and an M.S., both in Chemistry, from Seton Hall University, and a B.A. in Chemistry from New York University. He is also certified in US Regulatory Affairs.

Amicus Therapeutics Management Efficiency

The company has return on total asset (ROA) of (0.0612) % which means that it has lost $0.0612 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0704) %, meaning that it created substantial loss on money invested by shareholders. Amicus Therapeutics' management efficiency ratios could be used to measure how well Amicus Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of March 28, 2024, Return On Capital Employed is expected to decline to -0.13. In addition to that, Return On Assets is expected to decline to -0.2. At present, Amicus Therapeutics' Non Currrent Assets Other are projected to increase significantly based on the last few years of reporting. The current year's Fixed Asset Turnover is expected to grow to 7.23, whereas Other Assets are forecasted to decline to about 41.8 M.
The company currently holds 445.06 M in liabilities with Debt to Equity (D/E) ratio of 2.6, implying the company greatly relies on financing operations through barrowing. Amicus Therapeutics has a current ratio of 2.96, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Amicus Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Amicus Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Amicus Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Amicus to invest in growth at high rates of return. When we think about Amicus Therapeutics' use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 11 records

PRESIDENT Age

Michael TangAgilent Technologies
50
Jacob ThaysenAgilent Technologies
49
Dominique GrauAgilent Technologies
65
Henrik AncherJensenAgilent Technologies
59
Robert McMahonAgilent Technologies
55
Alicia RodriguezAgilent Technologies
N/A
Eilon AsculaiMediwound
N/A
Rodney GonsalvesAgilent Technologies
58
Samraat RahaAgilent Technologies
51
Mark DoakAgilent Technologies
63
Patrick KaltenbachAgilent Technologies
53
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania. Amicus Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 496 people. Amicus Therapeutics (FOLD) is traded on NASDAQ Exchange in USA. It is located in 47 Hulfish Street, Princeton, NJ, United States, 08542 and employs 517 people. Amicus Therapeutics is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Amicus Therapeutics Leadership Team

Elected by the shareholders, the Amicus Therapeutics' board of directors comprises two types of representatives: Amicus Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Amicus. The board's role is to monitor Amicus Therapeutics' management team and ensure that shareholders' interests are well served. Amicus Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Amicus Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Hung Do, Senior Vice President - Discovery Biology
Robert Essner, Independent Director
John Kirk, Vice President - Regulatory Affairs
David Clark, Chief Officer
Andrew Mulberg, Vice President - Regulatory Strategy
Craig Wheeler, Independent Director
Daphne Quimi, Principal Accounting Officer, VP of Fin. and Corporate Controller
Bradley Campbell, Pres and COO
Burke Whitman, Independent Director
Enrique Dilone, Vice President - Technical Operations
John Crowley, Executive Chairman
Dipal Doshi, Senior Vice President - Business Planning and Development
Mark Baldry, Vice President of Global Marketing
Margaret McGlynn, Independent Director
Samantha Prout, Principal Accounting Officer, Controller
Bradley MBA, President CEO
Andrew Faughnan, Director Relations
Diana Moore, Head Communications
Kenneth Peist, Vice President - Legal and Intellectual Property
Ken Valenzano, Senior Vice President - Preclinical Research
Ted Love, Independent Director
Jay Barth, Chief Medical Officer
Jayne Gershkowitz, Vice President - Patient Advocacy & Public Policy
Donald Hayden, Lead Independent Director
Patrik Esq, Global Officer
Michael Raab, Independent Director
Sara Pellegrino, IR Contact Officer
Willem Weperen, Regional Vice President and Country Manager, International
Sol Barer, Independent Director
Julie Yu, Vice President - Clinical Operations and Data Management
Patrik Florencio, Global VP
William Baird, CFO
David Allsop, Senior Vice President - International
Lynn Bleil, Independent Director
Simon Harford, Chief Officer
Ellen Rosenberg, General Counsel and Corporate Secretary
Simon Jordan, Senior Vice President - International
Jill Weimer, Senior Vice President of Discovery Research and Gene Therapy Science
Glenn Sblendorio, Independent Director
Jeffrey Castelli, Vice President - Program and Portfolio Management
Kurt Andrews, Senior Vice President - Human Resources

Amicus Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Amicus Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Amicus Therapeutics is a strong investment it is important to analyze Amicus Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Amicus Therapeutics' future performance. For an informed investment choice regarding Amicus Stock, refer to the following important reports:
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Amicus Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.
For information on how to trade Amicus Stock refer to our How to Trade Amicus Stock guide.
You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.

Complementary Tools for Amicus Stock analysis

When running Amicus Therapeutics' price analysis, check to measure Amicus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amicus Therapeutics is operating at the current time. Most of Amicus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Amicus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amicus Therapeutics' price. Additionally, you may evaluate how the addition of Amicus Therapeutics to your portfolios can decrease your overall portfolio volatility.
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Bonds Directory
Find actively traded corporate debentures issued by US companies
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Is Amicus Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amicus Therapeutics. If investors know Amicus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amicus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.51)
Revenue Per Share
1.353
Quarterly Revenue Growth
0.306
Return On Assets
(0.06)
Return On Equity
(1.07)
The market value of Amicus Therapeutics is measured differently than its book value, which is the value of Amicus that is recorded on the company's balance sheet. Investors also form their own opinion of Amicus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Amicus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amicus Therapeutics' market value can be influenced by many factors that don't directly affect Amicus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amicus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Amicus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amicus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.